Animas' development of a first-generation closed loop insulin delivery system progresses

February 28, 2013

WEST CHESTER, Pa., February 28, 2013 - Animas Corporation announced today positive results from the second phase of human clinical trials of a first-generation, closed-loop insulin delivery system in development, designed to predict a rise or fall in blood glucose and correspondingly increase, decrease, suspend and resume insulin delivery. The data were presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Paris, France.

The feasibility study of the predictive Hypoglycemia-Hyperglycemia Minimizer (HHM) System* in development was conducted in 20 adults with Type 1 diabetes and designed to investigate the System's ability to adjust insulin dosing to proactively mitigate hypoglycemia and hyperglycemia. The study, which was the first conducted in humans to investigate the configuration of the predictive algorithm, revealed differences in the algorithm's insulin-dosing characteristics and provided insights into the sensitivity of the System. The results also indicated that the System reduced insulin delivery in advance of hypoglycemia and triggered timely warnings. The study was conducted by Animas Corporation in partnership with leading academic research institutions, including the University of California, Santa Barbara; Sansum Diabetes Research Institute; and the Center for Diabetes Technology at the University of Virginia.

"We are encouraged by these results, which strengthen our understanding of the complex algorithms required of a closed-loop insulin delivery system and further our confidence in this technology platform," said Ramakrishna Venugopalan, Director, Research & Development at Animas Corporation. "The scope of this study also reflects our commitment to create innovative and robust solutions for people living with diabetes."

Animas began collaborating with industry, academia and advocacy organizations, including the JDRF (formerly the Juvenile Diabetes Research Foundation), in 2010. After receiving Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) in 2011, researchers began the first human clinical feasibility studies for the development of a closed-loop insulin delivery system. Together with these key partners, Animas continues to work toward developing such an automated system to help people living with Type 1 diabetes better control their disease.

"We are encouraged by the results and progress Animas has made in the first stage of development of a closed-loop insulin delivery system," said Aaron Kowalski, Ph.D., Vice President of Treatment Therapies Research at JDRF. "A predictive system that cannot only detect, but can predict blood sugar levels and make automatic adjustments to insulin delivery would be a major advance for people with Type 1 diabetes."

* The HHM System includes a continuous subcutaneous insulin infusion pump, a continuous glucose monitor (CGM) and a control algorithm used to predict changes in blood glucose.

About the Clinical Study

The study investigated the effect of a fundamental algorithm parameter on the quantitative insulin-dosing characteristics of the System. The parameter, known as the "aggressiveness factor," affects how readily the algorithm adjusts insulin delivery in response to glucose fluctuations. This is the first study in humans to investigate tuning such an algorithm parameter. The results demonstrated differences in the algorithm's insulin-dosing characteristics based on three aggressiveness factors and reinforced the importance of investigating the sensitivity of the System to its key parameters.

The study also investigated the predictive, proactive methods by which the System mitigates hypoglycemia, especially as compared to reactive, threshold-based systems. In particular, two predictive hypoglycemia safeguards of the System were investigated: its ability to decrease/suspend insulin delivery before a hypoglycemic threshold is reached, and its ability to trigger timely alerts for imminent hypoglycemia. The results indicated that the System reduced insulin delivery in advance of breaches of a hypoglycemic threshold and triggered timely warnings for imminent hypoglycemica.

Regarding general glucose control, the System demonstrated promising results, keeping glucose levels at an average of 133 mg/dL for the entire cohort. On average, 82.8 percent of the closed-loop time was spent at glucose levels between 70-180 mg/dL, and little time (3.4 percent) was spent at levels below 70 mg/dL. There were no safety concerns, including diabetic ketoacidosis or severe hypoglycemia.
-end-
About Animas Corporation

As part of the Johnson & Johnson Family of Companies, Animas is dedicated to creating a world without limits for people with diabetes through a wide range of products, including the OneTouch® Ping® Glucose Management System, Animas® Vibe™ insulin pump and CGM system and the Animas® 2020 insulin pump. Animas, from the Latin word meaning "true inner self or soul," has been committed since 1996 to meeting individual patient needs through the development of life-performance technology and customer service 24 hours a day, 7 days a week, 365 days a year. To learn more about Animas, visit http://www.animas.com/.

Tonic Life Communications USA

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.